InvestorsHub Logo
Followers 1
Posts 348
Boards Moderated 0
Alias Born 03/05/2019

Re: Midasbro post# 43136

Thursday, 07/11/2019 12:56:43 AM

Thursday, July 11, 2019 12:56:43 AM

Post# of 233755
"The retasking of CCR5 inhibitors for cancer prevention and treatment of metastatic cancer
leverages the substantial prior clinical experience with these compounds and their known safety
profiles in patients with HIV. Several additional agents, when combined with CCR5 inhibitors
have shown promise in preclinical studies including anti-IL-6 receptor antibody for TNBC and
PDL-1 inhibitors in gastric and colon cancer. The finding that CCR5 inhibitors enhance cancer
cell killing mediated by radiation and DNA-damaging chemotherapeutic agents (5) suggests the
potential for combining these biological agents with chemotherapeutics in order to potentially
reduce the dose-dependent side-effects of chemotherapy."
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News